|
Delayed
Nasdaq
13:48:22 29/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 10.28 USD | -3.20% |
|
-1.53% | +67.15% |
| 10-12 | ImmuCell Q3 Preliminary Sales Rise | MT |
| 10-12 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Business description: ImmuCell Corporation

Number of employees: 73
Sales by Activity: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Scours | - | 18.41M | 17.29M | 26.31M | 27.45M |
Mastitis | - | 155K | 178K | 179K | 196K |
Biotechnology | 19.24M | - | - | - | - |
Other | - | 1.46K | - | - | - |
Geographical breakdown of sales: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.62M | 17.02M | 15.95M | 22.89M | 24.39M |
Other | 2.62M | 1.55M | 1.52M | 3.6M | 3.25M |
Executive Committee: ImmuCell Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 31/10/2025 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 06/04/2025 |
| Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: ImmuCell Corporation
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 30/11/2013 |
Paul Wainman
BRD | Director/Board Member | 61 | 30/03/2014 |
Gloria Basse
BRD | Director/Board Member | 66 | 09/06/2020 |
| Director/Board Member | 54 | 31/10/2025 | |
Kathy Turner
BRD | Director/Board Member | 62 | 31/03/2026 |
| Director/Board Member | 64 | 14/04/2026 | |
Anthony DiMarco
BRD | Director/Board Member | 63 | 14/04/2026 |
Company details: ImmuCell Corporation

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.20% | -1.53% | +70.48% | +108.52% | 96.45M | ||
| +7.73% | +6.32% | +70.77% | +145.58% | 1,148B | ||
| +1.41% | +2.95% | +47.64% | +87.38% | 652B | ||
| +1.65% | +2.04% | +29.26% | +105.10% | 505B | ||
| +0.79% | +2.78% | +54.76% | +67.01% | 384B | ||
| +4.41% | +0.76% | +71.36% | +44.49% | 348B | ||
| +2.90% | +3.52% | +35.45% | +57.65% | 294B | ||
| +2.24% | +0.85% | +4.22% | +28.11% | 264B | ||
| +2.88% | +4.06% | +59.53% | +76.85% | 244B | ||
| +1.96% | +3.30% | +37.02% | +108.78% | 197B | ||
| Average | +2.46% | +1.34% | +48.05% | +82.95% | 403.73B | |
| Weighted average by Cap. | +3.76% | +1.50% | +51.12% | +94.89% |
- Stock Market
- Stocks
- ICCC Stock
- Company ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions

















